Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£1.12|
|52 Week High||UK£0.60|
|52 Week Low||UK£2.50|
|1 Month Change||-5.11%|
|3 Month Change||-9.72%|
|1 Year Change||52.74%|
|3 Year Change||42.95%|
|5 Year Change||n/a|
|Change since IPO||-48.74%|
Recent News & Updates
Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Destiny Pharma ( LON:DEST...
Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|DEST||GB Biotechs||GB Market|
Return vs Industry: DEST exceeded the UK Biotechs industry which returned 23.6% over the past year.
Return vs Market: DEST exceeded the UK Market which returned 22.9% over the past year.
Stable Share Price: DEST is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: DEST's weekly volatility has decreased from 10% to 5% over the past year.
About the Company
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm for the treatment of of antibiotic resistant biofilm and bacterial aggregate associated infections.
Destiny Pharma Fundamentals Summary
|DEST fundamental statistics|
Is DEST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DEST income statement (TTM)|
|Cost of Revenue||UK£0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.091|
|Net Profit Margin||-43,931.60%|
How did DEST perform over the long term?See historical performance and comparison
Is Destiny Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DEST is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.
PE vs Market: DEST is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DEST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DEST is overvalued based on its PB Ratio (6.6x) compared to the GB Biotechs industry average (6.3x).
How is Destiny Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Destiny Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Destiny Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DEST is currently unprofitable.
Growing Profit Margin: DEST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DEST is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.
Accelerating Growth: Unable to compare DEST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DEST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: DEST has a negative Return on Equity (-53.81%), as it is currently unprofitable.
How is Destiny Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: DEST's short term assets (£8.2M) exceed its short term liabilities (£349.4K).
Long Term Liabilities: DEST has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: DEST is debt free.
Reducing Debt: DEST has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DEST has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DEST has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 34.4% each year.
What is Destiny Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DEST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DEST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DEST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DEST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DEST's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Neil Clark (58 yo)
Mr. Neil Robert Clark, BSc, FCA, has been the Chief Executive Officer and Executive Director at Destiny Pharma plc since April 13, 2017 and January 20, 2017 respectively. Mr. Clark has been Consultant of P...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD447.24K) is above average for companies of similar size in the UK market ($USD330.27K).
Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.
Experienced Management: DEST's management team is considered experienced (3.1 years average tenure).
Experienced Board: DEST's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DEST insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.5%.
Destiny Pharma plc's employee growth, exchange listings and data sources
- Name: Destiny Pharma plc
- Ticker: DEST
- Exchange: AIM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£66.746m
- Shares outstanding: 59.86m
- Website: https://www.destinypharma.com
Number of Employees
- Destiny Pharma plc
- Sussex Innovation Centre
- Unit 36
- East Sussex
- BN1 9SB
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 17:48|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.